Novel Bone Drug Promising in Postmenopausal Osteoporosis
U.S. & Europe Evaluate Abaloparatide Injection & Europe Approves Marketing Baricitinib for RA
The Gut Microbiome Influences Postmenopausal Bone Loss
Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz
Abaloparatide May Boost BMD in Older Women with Osteoporosis
Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis
